Shopping Cart 0
Cart Subtotal
USD 0

Helix BioPharma Corp (HBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company's proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp (HBP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Helix BioPharma Plans Partnership For L-DOS47 12

Helix Biopharma Enters into Agreement with ProMab Biotechnologies 13

Helix BioPharma and Moffitt Cancer Center Enter into Agreement 14

Licensing Agreements 15

Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 15

Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 16

Helix Polska Enters into Licensing Agreement with Helix BioPharma 17

Equity Offering 18

Helix BioPharma Raises USD0.3 Million in Private Placement of Units 18

Helix BioPharma Raises USD0.8 Million in Private Placement of Units 19

Helix BioPharma Raises USD0.5 Million in Private Placement of Units 20

Helix BioPharma Raises USD0.6 Million in Private Placement of Units 21

Helix BioPharma Raises USD3 Million in Private Placement of Units 22

Helix BioPharma Raises USD1 Million in Private Placement of Units 23

Helix BioPharma Raises USD2.3 Million in Private Placement of Units 24

Helix BioPharma Raises USD0.6 Million in Private Placement of Units 25

Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 26

Helix BioPharma Raises USD1 Million in Private Placement of Units 27

Helix BioPharma Raises USD1.4 Million in Private Placement of Units 28

Helix BioPharma Raises USD3.58 Million in Private Placement of Units 29

Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 30

Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 31

Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 32

Helix BioPharma Completes Private Placement Of Common Stock And Warrants 33

Asset Transactions 34

Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For USD 8.6 Million 34

Helix BioPharma Corp-Key Competitors 35

Helix BioPharma Corp-Key Employees 36

Helix BioPharma Corp-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Jun 12, 2018: Helix BioPharma Reports Fiscal Third Quarter 2018 Financial Results 38

Mar 20, 2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results 40

Dec 13, 2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results 42

Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 43

Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 45

Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 47

Corporate Communications 48

Mar 22, 2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board 48

Dec 01, 2017: Helix BioPharma Announces Management Change 49

Jul 17, 2017: Helix BioPharma Director Resigns 50

Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 51

Product News 52

04/03/2017: Helix BioPharma to Present CAR-T at AACR Annual Meeting 2017 in Washington, D.C. 52

01/23/2017: Helix BioPharma Announces CAR-T Poster Presentation at AACR Annual Meeting 2017 in Washington, DC 53

Other Significant Developments 54

Sep 12, 2018: Helix BioPharma collaborator ProMab Biotechnologies publishes paper on multiple myeloma CAR-T 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Helix BioPharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Helix BioPharma Plans Partnership For L-DOS47 12

Helix Biopharma Enters into Agreement with ProMab Biotechnologies 13

Helix BioPharma and Moffitt Cancer Center Enter into Agreement 14

Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 15

Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 16

Helix Polska Enters into Licensing Agreement with Helix BioPharma 17

Helix BioPharma Raises USD0.3 Million in Private Placement of Units 18

Helix BioPharma Raises USD0.8 Million in Private Placement of Units 19

Helix BioPharma Raises USD0.5 Million in Private Placement of Units 20

Helix BioPharma Raises USD0.6 Million in Private Placement of Units 21

Helix BioPharma Raises USD3 Million in Private Placement of Units 22

Helix BioPharma Raises USD1 Million in Private Placement of Units 23

Helix BioPharma Raises USD2.3 Million in Private Placement of Units 24

Helix BioPharma Raises USD0.6 Million in Private Placement of Units 25

Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 26

Helix BioPharma Raises USD1 Million in Private Placement of Units 27

Helix BioPharma Raises USD1.4 Million in Private Placement of Units 28

Helix BioPharma Raises USD3.58 Million in Private Placement of Units 29

Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 30

Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 31

Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 32

Helix BioPharma Completes Private Placement Of Common Stock And Warrants 33

Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For USD 8.6 Million 34

Helix BioPharma Corp, Key Competitors 35

Helix BioPharma Corp, Key Employees 36

Helix BioPharma Corp, Subsidiaries 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Helix BioPharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company's proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp (HBP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Helix BioPharma Plans Partnership For L-DOS47 12

Helix Biopharma Enters into Agreement with ProMab Biotechnologies 13

Helix BioPharma and Moffitt Cancer Center Enter into Agreement 14

Licensing Agreements 15

Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 15

Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 16

Helix Polska Enters into Licensing Agreement with Helix BioPharma 17

Equity Offering 18

Helix BioPharma Raises USD0.3 Million in Private Placement of Units 18

Helix BioPharma Raises USD0.8 Million in Private Placement of Units 19

Helix BioPharma Raises USD0.5 Million in Private Placement of Units 20

Helix BioPharma Raises USD0.6 Million in Private Placement of Units 21

Helix BioPharma Raises USD3 Million in Private Placement of Units 22

Helix BioPharma Raises USD1 Million in Private Placement of Units 23

Helix BioPharma Raises USD2.3 Million in Private Placement of Units 24

Helix BioPharma Raises USD0.6 Million in Private Placement of Units 25

Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 26

Helix BioPharma Raises USD1 Million in Private Placement of Units 27

Helix BioPharma Raises USD1.4 Million in Private Placement of Units 28

Helix BioPharma Raises USD3.58 Million in Private Placement of Units 29

Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 30

Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 31

Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 32

Helix BioPharma Completes Private Placement Of Common Stock And Warrants 33

Asset Transactions 34

Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For USD 8.6 Million 34

Helix BioPharma Corp-Key Competitors 35

Helix BioPharma Corp-Key Employees 36

Helix BioPharma Corp-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Jun 12, 2018: Helix BioPharma Reports Fiscal Third Quarter 2018 Financial Results 38

Mar 20, 2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results 40

Dec 13, 2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results 42

Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 43

Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 45

Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 47

Corporate Communications 48

Mar 22, 2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board 48

Dec 01, 2017: Helix BioPharma Announces Management Change 49

Jul 17, 2017: Helix BioPharma Director Resigns 50

Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 51

Product News 52

04/03/2017: Helix BioPharma to Present CAR-T at AACR Annual Meeting 2017 in Washington, D.C. 52

01/23/2017: Helix BioPharma Announces CAR-T Poster Presentation at AACR Annual Meeting 2017 in Washington, DC 53

Other Significant Developments 54

Sep 12, 2018: Helix BioPharma collaborator ProMab Biotechnologies publishes paper on multiple myeloma CAR-T 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Helix BioPharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Helix BioPharma Plans Partnership For L-DOS47 12

Helix Biopharma Enters into Agreement with ProMab Biotechnologies 13

Helix BioPharma and Moffitt Cancer Center Enter into Agreement 14

Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 15

Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 16

Helix Polska Enters into Licensing Agreement with Helix BioPharma 17

Helix BioPharma Raises USD0.3 Million in Private Placement of Units 18

Helix BioPharma Raises USD0.8 Million in Private Placement of Units 19

Helix BioPharma Raises USD0.5 Million in Private Placement of Units 20

Helix BioPharma Raises USD0.6 Million in Private Placement of Units 21

Helix BioPharma Raises USD3 Million in Private Placement of Units 22

Helix BioPharma Raises USD1 Million in Private Placement of Units 23

Helix BioPharma Raises USD2.3 Million in Private Placement of Units 24

Helix BioPharma Raises USD0.6 Million in Private Placement of Units 25

Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 26

Helix BioPharma Raises USD1 Million in Private Placement of Units 27

Helix BioPharma Raises USD1.4 Million in Private Placement of Units 28

Helix BioPharma Raises USD3.58 Million in Private Placement of Units 29

Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 30

Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 31

Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 32

Helix BioPharma Completes Private Placement Of Common Stock And Warrants 33

Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For USD 8.6 Million 34

Helix BioPharma Corp, Key Competitors 35

Helix BioPharma Corp, Key Employees 36

Helix BioPharma Corp, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Helix BioPharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.